Company Conducts Major Trial for Alzheimer’s Treatment

Photo by Robina Weermeijer on Unsplash

( – The Alzheimer’s Association has released new data that indicates a nationwide surge in the number of Alzheimer’s cases, while the healthcare industry is experiencing a shortage of dementia care workers.

Eli Lilly has been trialing a new experimental treatment that could slow the progress of cognitive and functional degradation for those who exhibit early Alzheimer’s symptoms. The company revealed the sizeable clinical trial on Wednesday, noting that during their 18-month long trial period, close to 1,700 patients had a decline in the rate of memory loss and the ability to take on daily tasks. According to the test results, these results were 35 percent higher than the results exhibited by those who were given a placebo.

The company has stated that they plan to seek approval from the Food and Drug Administration (FDA), while pointing out that these are the most promising results that any Alzheimer’s medication has ever had at this stage of a clinical trial. Donanemab, if approved by the FDA, could be particularly important for those exhibiting early signs of Alzheimer’s, as it would give them the power to continue performing their daily activities.

Anne White, who is the executive vice president of Eli Lilly and Company and president of Lilly Neuroscience, also released a statement praising the results of the medication, which still has yet to be peer-reviewed.

However, the positive results could potentially be overthrown by the fact that two participants passed away from bleeding or swelling of the brain, which is sometimes the result of medications of its kind. A third person involved in the study might also have passed away because of these side effects, according to the study.

Copyright 2023,